BioCentury | Jun 6, 2020
Finance

Daily Chart: NASDAQ’s dazzling debuts

...Biotechnology Co. Ltd. Applied Molecular Transport Inc Pliant Therapeutics Inc. Ayala Pharmaceuticals Inc. Lyra Therapeutics Inc. ORIC Pharmaceuticals Inc. Keros Therapeutics Inc. Zentalis Pharmaceuticals Inc. Imara...
BioCentury | May 22, 2020
Product Development

May 21 Quick Takes: EC approves Zolgensma for SMA; plus Sunovion, Kadmon, Sorrento, tafasitamab, Zentalis’ new JV

...stem cell transplantation. FDA granted the combination Priority Review in March. Zentalis launches Shanghai-based JV Zentalis Pharmaceuticals Inc....
...of motor neuron 2 centromeric Robin Sawka, BioCentury Staff Kadmon Holdings Inc. Sorrento Therapeutics Inc. Novartis AG AveXis Inc. Incyte Corp. MorphoSys AG Zentalis Pharmaceuticals Inc. Bruton's...
BioCentury | May 21, 2020
Product Development

May 20 Quick Takes: Filgotinib meets in ulcerative colitis; broader labels for Lynparza, Tecentriq, plus updates from Eiger, eGenesis and more

...#), atezolizumab (Generic), Tecentriq (Other), Anti-PDL1 (Other) filgotinib (GLPG0634, GS-6034) Sarasar, lonafarnib (mk-6336, sch 066336) SRF617 Keytruda, pembrolizumab (MK-3475, lambrolizumab) Zentalis Pharmaceuticals Inc. Gilead...
BioCentury | May 15, 2020
Finance

As biotech IPO pace quickens, ADC Therapeutics garners largest postmoney valuation of the year

...precipitously. A handful of companies managed to list during that period: Keros Therapeutics Inc. (NASDAQ:KROS), Zentalis Pharmaceuticals Inc....
BioCentury | May 13, 2020
Finance

Daily Chart: NASDAQ IPOs forge ahead

...first-day gains, and all three -- ORIC Pharmaceuticals Inc. (NASDAQ:ORIC), Keros Therapeutics Inc. (NASDAQ:KROS) and Zentalis Pharmaceuticals Inc....
BioCentury | May 11, 2020
Finance

Third Rock-backed fibrosis company Pliant joins IPO queue

...least 26%, and all three -- ORIC Pharmaceuticals Inc. (NASDAQ:ORIC), Keros Therapeutics Inc. (NASDAQ:KROS) and Zentalis Pharmaceuticals Inc....
BioCentury | May 1, 2020
Finance

As market’s upbeat April draws to close, Lyra becomes latest biotech IPO to surge

...least 26%, and all three -- ORIC Pharmaceuticals Inc. (NASDAQ:ORIC), Keros Therapeutics Inc. (NASDAQ:KROS) and Zentalis Pharmaceuticals Inc....
BioCentury | Apr 24, 2020
Finance

Big gain for ORIC in trading debut after pricing upsized IPO

...above expectations. With its market debut on Friday, ORIC joins Keros Therapeutics Inc. (NASDAQ:KROS) and Zentalis Pharmaceuticals Inc....
BioCentury | Apr 9, 2020
Finance

Keros rises 26% in trading debut during week of market gains

...since the spread of COVID-19 began to upend the markets in late February. Last week, Zentalis Pharmaceuticals Inc....
BioCentury | Apr 3, 2020
Finance

Oncology company Zentalis posts double-digit gain after pricing upsized IPO

...receptive to new biopharma listings, even amid weeks of uncertainty due to the COVID-19 outbreak. Zentalis Pharmaceuticals Inc....
...IPO price (see “Cratering Market Spoils Debut” ; “Passage Prices Upsized IPO” ). Paul Bonanos, Associate Editor Zentalis Pharmaceuticals Inc. IPO...
Items per page:
1 - 10 of 11
BioCentury | Jun 6, 2020
Finance

Daily Chart: NASDAQ’s dazzling debuts

...Biotechnology Co. Ltd. Applied Molecular Transport Inc Pliant Therapeutics Inc. Ayala Pharmaceuticals Inc. Lyra Therapeutics Inc. ORIC Pharmaceuticals Inc. Keros Therapeutics Inc. Zentalis Pharmaceuticals Inc. Imara...
BioCentury | May 22, 2020
Product Development

May 21 Quick Takes: EC approves Zolgensma for SMA; plus Sunovion, Kadmon, Sorrento, tafasitamab, Zentalis’ new JV

...stem cell transplantation. FDA granted the combination Priority Review in March. Zentalis launches Shanghai-based JV Zentalis Pharmaceuticals Inc....
...of motor neuron 2 centromeric Robin Sawka, BioCentury Staff Kadmon Holdings Inc. Sorrento Therapeutics Inc. Novartis AG AveXis Inc. Incyte Corp. MorphoSys AG Zentalis Pharmaceuticals Inc. Bruton's...
BioCentury | May 21, 2020
Product Development

May 20 Quick Takes: Filgotinib meets in ulcerative colitis; broader labels for Lynparza, Tecentriq, plus updates from Eiger, eGenesis and more

...#), atezolizumab (Generic), Tecentriq (Other), Anti-PDL1 (Other) filgotinib (GLPG0634, GS-6034) Sarasar, lonafarnib (mk-6336, sch 066336) SRF617 Keytruda, pembrolizumab (MK-3475, lambrolizumab) Zentalis Pharmaceuticals Inc. Gilead...
BioCentury | May 15, 2020
Finance

As biotech IPO pace quickens, ADC Therapeutics garners largest postmoney valuation of the year

...precipitously. A handful of companies managed to list during that period: Keros Therapeutics Inc. (NASDAQ:KROS), Zentalis Pharmaceuticals Inc....
BioCentury | May 13, 2020
Finance

Daily Chart: NASDAQ IPOs forge ahead

...first-day gains, and all three -- ORIC Pharmaceuticals Inc. (NASDAQ:ORIC), Keros Therapeutics Inc. (NASDAQ:KROS) and Zentalis Pharmaceuticals Inc....
BioCentury | May 11, 2020
Finance

Third Rock-backed fibrosis company Pliant joins IPO queue

...least 26%, and all three -- ORIC Pharmaceuticals Inc. (NASDAQ:ORIC), Keros Therapeutics Inc. (NASDAQ:KROS) and Zentalis Pharmaceuticals Inc....
BioCentury | May 1, 2020
Finance

As market’s upbeat April draws to close, Lyra becomes latest biotech IPO to surge

...least 26%, and all three -- ORIC Pharmaceuticals Inc. (NASDAQ:ORIC), Keros Therapeutics Inc. (NASDAQ:KROS) and Zentalis Pharmaceuticals Inc....
BioCentury | Apr 24, 2020
Finance

Big gain for ORIC in trading debut after pricing upsized IPO

...above expectations. With its market debut on Friday, ORIC joins Keros Therapeutics Inc. (NASDAQ:KROS) and Zentalis Pharmaceuticals Inc....
BioCentury | Apr 9, 2020
Finance

Keros rises 26% in trading debut during week of market gains

...since the spread of COVID-19 began to upend the markets in late February. Last week, Zentalis Pharmaceuticals Inc....
BioCentury | Apr 3, 2020
Finance

Oncology company Zentalis posts double-digit gain after pricing upsized IPO

...receptive to new biopharma listings, even amid weeks of uncertainty due to the COVID-19 outbreak. Zentalis Pharmaceuticals Inc....
...IPO price (see “Cratering Market Spoils Debut” ; “Passage Prices Upsized IPO” ). Paul Bonanos, Associate Editor Zentalis Pharmaceuticals Inc. IPO...
Items per page:
1 - 10 of 11